Digest Network Come funziona
Network
/
Società
Av
Non verificato

Avenzo Therapeutics, Inc.

Di cosa scriviamo

BiotecnologiaFarmaceuticaMedicina - VarieOncologiaSalute

22 comunicati stampa

Guarda tutti i comunicati
01/06/2026
Eventi
Industria
Biotecnologia
Salute
Farmaceutica
Medicina - Varie
Oncologia
Avenzo Therapeutics Presents Updated Results from the Phase 1/2 Study of AVZO-021, a Potentially Differentiated CDK2 Inhibitor, at the 2026 American Society of Clinical Oncology Annual Meeting
Fonte
Avenzo Therapeutics, Inc.
Emittente
Business Wire
1.00
0
28/05/2026
Biotecnologia
Salute
Farmaceutica
Medicina - Varie
Oncologia
Eventi
Industria
Avenzo Therapeutics Announces First Patient Dosed in Combination Cohort Evaluating CDK4 Selective Inhibitor (AVZO-023) with CDK2 Selective Inhibitor (AVZO-021) In Ongoing Phase 1/2 ORION-1 Study
Fonte
Avenzo Therapeutics, Inc.
Emittente
Business Wire
1.00
0
28/04/2026
Industria
Biotecnologia
Salute
Farmaceutica
Medicina - Varie
Oncologia
Avenzo Therapeutics Advances the Combination of CDK4 Selective Inhibitor (AVZO-023) with CDK2 Selective Inhibitor (AVZO-021) in Ongoing Phase 1/2 ORION-1 Study in HR+/HER2- Breast Cancer
Fonte
Avenzo Therapeutics, Inc.
Emittente
Business Wire
1.00
0
21/04/2026
Eventi
Industria
Biotecnologia
Salute
Farmaceutica
Medicina - Varie
Oncologia
Avenzo Therapeutics to Present Updated Results from the Phase 1 Study of AVZO-021, a Potential Best-in-Class CDK2 Inhibitor, at the 2026 American Society of Clinical Oncology Annual Meeting
Fonte
Avenzo Therapeutics, Inc.
Emittente
Business Wire
1.00
0
11/12/2025
Industria
Eventi
Oncologia
Salute
Medicina - Varie
Scienza
Farmaceutica
Biotecnologia
Avenzo Therapeutics Presents Initial Results from the Phase 1/2 Study of AVZO-021, a Potential Best-in-Class CDK2 Inhibitor, at the 2025 San Antonio Breast Cancer Symposium
Fonte
Avenzo Therapeutics, Inc.
Emittente
Business Wire
1.00
0
24/11/2025
Oncologia
Igiene alimentare
Salute
Medicina - Varie
Farmaceutica
Biotecnologia
Industria
Avenzo Therapeutics Granted Fast Track Designation for AVZO-103, a Potential Best-in-Class Nectin4/TROP2 Bispecific Antibody-Drug Conjugate, for the Treatment of Patients with Urothelial Cancer Previously Treated with Enfortumab Vedotin
Fonte
Avenzo Therapeutics, Inc.
Emittente
Business Wire
1.00
0
19/11/2025
Oncologia
Attrezzature medico-sanitarie
Salute
Medicina - Varie
Farmaceutica
Biotecnologia
Mercato del lavoro
Avenzo Therapeutics Announces Appointment of Scott Lipman as Chief Financial Officer
Fonte
Avenzo Therapeutics, Inc.
Emittente
Business Wire
1.00
0
10/11/2025
Oncologia
Salute
Igiene alimentare
Sanità
Medicina - Varie
Farmaceutica
Biotecnologia
Industria
Avenzo Therapeutics Granted Fast Track Designation for AVZO-1418, a Potential Best-in-Class EGFR/HER3 Bispecific Antibody-Drug Conjugate, for the Treatment of Patients with EGFR-Mutated TKI-Pretreated NSCLC
Fonte
Avenzo Therapeutics, Inc.
Emittente
Business Wire
1.00
0
30/10/2025
Eventi
Scienza
Medicina - Varie
Biotecnologia
Salute
Farmaceutica
Sanità
Oncologia
Avenzo Therapeutics to Present Initial Results from the Phase 1 Study of AVZO-021, a Potential Best-in-Class CDK2 Inhibitor, at the 2025 San Antonio Breast Cancer Symposium
Fonte
Avenzo Therapeutics, Inc.
Emittente
Business Wire
1.00
0
29/09/2025
Oncologia
Salute
Medicina - Varie
Scienza
Farmaceutica
Biotecnologia
Industria
Avenzo Therapeutics Initiates Phase 1/2 Clinical Study of AVZO-103, a Potential Best-in-Class Nectin4/TROP2 Bispecific Antibody-Drug Conjugate
Fonte
Avenzo Therapeutics, Inc.
Emittente
Business Wire
1.00
0

Recapiti

Social Media

Seguaci
0
Compatibilità
0